Autoimmune diseases are pathologies caused by a loss of immune tolerance to multiple autoantigens, targeting specific cell types, tissues or organs, or by a systemic immune response. For most autoimmune diseases, induction of autoantigen-specific regulatory T cells has become the therapeutic option of choice. Many studies have shown that pMHC-based nanomedicines can induce and amplify disease-suppressing regulatory T cells and are capable of fully suppressing organ-specific autoimmunity without compromising normal immunity.
As an expert in the field of MHC, Creative BioMart can provide pMHC-NPs new therapeutic development services, offering solutions for the development of nanoparticles coated with pMHC to induce regulatory T cells in vivo, which can treat a variety of autoimmune diseases such as type 1 diabetes, multiple sclerosis, and allergies.
pMHC-NPs can promote the formation and expansion of antigen-specific Treg cells and suppress many autoimmune responses. In such nanoparticles, pMHC represents specific antigens that are attached to nanoparticles composed of iron oxide nanoparticles via PEG joints, which can send profound and sustained signals to homologous T cells. It promotes the differentiation of pre-activated auto-reactive CD4+ T cells into TR1-like cells and their systemic expansion, which then suppress auto-reactive helper and cytotoxic T cells by secreting IL-10, TGFβ, etc., thus resolving complex autoimmune diseases.
Fig.1 Induction of antigen-specific Treg cells by pMHC-NPs (Yang Y and Pere S, 2022)
Creative BioMart is dedicated to the research and development of MHC-based nanomedicines to provide satisfactory answers to our customers' autoimmune disease treatment programs. Please do not hesitate to contact us.
References
Tel:
One-stop service